Actym Therapeutics, Inc.

Actym Therapeutics, Inc. , based in Berkeley, US, is a biotechnology company focused on developing innovative cancer therapies using its STACT™ platform, which employs engineered bacterial systems for targeted treatment delivery. Actym Therapeutics, Inc. was founded in 2017 in Berkeley, California, and is engaged in developing cancer treatments.

The company has closed three investment deals to date, with the latest funding round occurring on June 28, 2023. Actym raised USD 11. 238 mn during its Series A funding round, co-led by Boehringer Ingelheim Venture Fund and Illumina Ventures, among others. The current CEO and founder is Christopher Thanos, who has a history in the biotech sector.

Actym Therapeutics specializes in innovative cancer treatments through its STACT™ (S. Typhimurium Anti-Cancer Therapy) platform, which leverages engineered bacterial delivery systems. This platform allows for the systemic administration of therapeutic payloads, specifically designed to amplify and produce therapeutic agents at the disease site, minimizing the systemic toxicity commonly associated with traditional delivery methods. Actym's flagship product, ACTM-838, is currently undergoing evaluation in a phase 1a/1b clinical trial targeting patients with advanced solid tumors.

The company primarily serves healthcare providers and oncologists in North America and Europe, focusing on institutions and clinics that specialize in cancer care and research, with the goal of improving patient outcomes in oncology and fibrotic diseases. Actym Therapeutics generates revenue through strategic partnerships and clinical trial collaborations aimed at advancing its proprietary therapies. Transactions typically occur on a business-to-business (B2B) basis, involving healthcare institutions and pharmaceutical companies that may seek to integrate Actym’s innovative therapies into their treatment protocols. These collaborations often involve milestone payments tied to the progress of clinical trials, along with potential licensing agreements for the use of Actym’s technology in various therapeutic applications.

Specific pricing plans or detailed financial arrangements are structured around the development and commercialization of products, particularly the STACT™ platform and its associated therapies. In June 2023, Actym Therapeutics, Inc. raised USD 11. 238 mn in Series A funding, aimed at advancing its pipeline of therapies and expanding its market reach.

The financing, co-led by Boehringer Ingelheim Venture Fund and Illumina Ventures, will support the development of new products, including the further clinical evaluation of ACTM-838. Furthermore, Actym plans to explore opportunities in new geographical markets, particularly targeting Europe and Asia, by 2024, as it seeks to enhance its presence in the oncology treatment landscape.